Search company, investor...

Stage

Other Investors | Alive

About Nanotope

Nanotope is a regenerative medicine company that leverages a core set of technologies to address multiple therapeutic markets. Nanotope is developing a suite of products, each customized to regenerate specific tissues; including neuronal, vascular, bone, myocardial, and cartilage. The products are injectable compounds that work with surviving cells in and around the point of damage to initiate and support tissue regeneration and growth. Once regeneration is complete, the compounds are safely broken down and removed by the body. Nanotope's lead products target neuron regeneration for prevention or reversal of paralysis associated with spinal cord injury and angiogenesis for wound healing and the treatment of peripheral artery disease.n

Headquarters Location

8025 Lamon Avenue, Suite 450

Aurora, Colorado, 60077,

United States

Loading...

Loading...

Nanotope Patents

Nanotope has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/16/2008

12/13/2011

Tissue engineering, Biomaterials, Food additives, Polymers, Molecular biology

Grant

Application Date

4/16/2008

Grant Date

12/13/2011

Title

Related Topics

Tissue engineering, Biomaterials, Food additives, Polymers, Molecular biology

Status

Grant

Nanotope Frequently Asked Questions (FAQ)

  • Where is Nanotope's headquarters?

    Nanotope's headquarters is located at 8025 Lamon Avenue, Suite 450, Aurora.

  • What is Nanotope's latest funding round?

    Nanotope's latest funding round is Other Investors.

  • Who are the investors of Nanotope?

    Investors of Nanotope include Fitzsimons Colorado Science and Technology Park.

  • Who are Nanotope's competitors?

    Competitors of Nanotope include Regentis Biomaterials, FirstString Research, OcuNexus Therapeutics, Banyan Biomarkers, Acorda Therapeutics and 7 more.

Loading...

Compare Nanotope to Competitors

B
Biofisica

Biofisica develops and markets products for soft tissue wound healing and tissue regeneration based on an exclusive and technology that uses electrical stimulation and hydro-gel materials.

F
FirstString Research

FirstString Research is a biopharmaceutical company focused on the development of drugs using its proprietary alpha-connexin carboxyl-terminus 1 (aCT1) peptide technology. The company's main offerings include treatments designed to revolutionize the body's response to injury, with applications in dermatology, ophthalmology, and pulmonology. It is based in Mount Pleasant, South Carolina.

N
Nimura Genetic Solutions

Isolating diverse creatures including species indegenous to rainforests in Malaysia, exploring new compounds which lead development of new medicine conforming to CBD and building a predominant bio-resource collection, NGS will contribute to health and progress of bioindustries in international community.

O
OcuNexus Therapeutics

OcuNexus Therapeutics is a clinical-stage company focused on the healthcare sector, specifically in the development of treatments for diseases where the inflammasome pathway of inflammation is dysregulated. The company's main product is a small molecule, administered orally once a day, that targets the pathologically open Connexin43 Hemichannel, which is responsible for inflammasome mediated autoinflammation in several disease states. The company primarily sells to the ophthalmology and nephrology sectors, with a focus on conditions such as diabetic retinopathy, diabetic nephropathy, and the intermediate stage of macular degeneration. OcuNexus Therapeutics was formerly known as CoDa Therapeutics. It was founded in 2005 and is based in San Diego, California.

L
Lead Pharma

Lead Pharma is a clinical-stage pharmaceutical research and development company, operating in the healthcare and pharmaceutical industry. The company's main focus is on designing and developing innovative small-molecule therapies, primarily aimed at treating autoimmune diseases and cancer. Lead Pharma primarily serves the healthcare sector, with a particular emphasis on the pharmaceutical industry. It is based in Oss, Netherlands.

A
AugmentRx

AugmentRx has developed a tissue bulking agent to treat stress urinary incontinence. The SOLVE injectable product aims to provide a fully viable alternative to slings, surgical procedures and inferior shorter-acting bulking agents. Per AugmentRx, it is bioinert, non-antigenic, non-migratory, permanent, easy-to-inject, and more affordable and aims to provide long-lasting, sustainable tissue volume.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.